Navin Fluorine International Limited share price

NSE: NAVINFLUOR · ISIN INE048G01026

Key numbers

Market cap
₹ 44,045 Cr
Current price
₹ 8,584.50
52-week high / low
₹ 8,950 / 4,499
Stock P/E
55.8
Book value
₹ 775.6
Dividend yield
0.18%
ROCE
21.2%
ROE
20.1%
Debt to equity
0.32
Sales growth (3 yrs)
16.5%
Profit growth (3 yrs)
20.9%
1-year return
83.0%

About Navin Fluorine International Limited

Navin Fluorine International Limited manufactures and sells specialty fluorochemicals in India and internationally. The company offers refrigerants for various applications, including room air conditioning, commercial refrigeration, industrial cooling, mobile air conditioning, cold chain, and heat pumps under the Mafron brand for original equipment manufacturers, service technicians, and equipment owners. It also provides inorganic fluoride products, such as hydrogen fluoride, diluted hydrofluoric acid, ammonium bifluoride, potassium fluoride, sodium fluoride, hexafluorophosphoric acid, hydrogen fluoride–pyridine complex, and fluoboric acid for oil and gas, steel and abrasives, industrial glass and specialty performance materials, pharmaceutical and agrochemicals, and medical surface treatment applications; and specialty fluorochemicals comprising benzotrifluoride, 2-chloro-5-(trifluoromethyl)pyridine, 4-fluorophenol, 3-aminobenzotrifluoride, 4-fluorobenzonitrile, 4-fluorobenzoic acid, and 3-chlorobenzotrifluoride. The company was founded in 1967 and is based in Mumbai, India.

Quarterly results

Consolidated figures in ₹ crores

Mar 2025Jun 2025Dec 2025Mar 2026Jun 2026
Sales7017258929381,045
Operating profit179207308321357
Net profit95117185213243
EPS (₹)19.1523.6336.1841.4947.45

Investor presentation summary (2026-09-07)

AI summary of the presentation · tone: Positive · source document

Key numbers

  • ✓ Capex for additional HFC capacity equivalent upto 15,000 MTPA of R32 is on track to
  • Net Revenue from Operations 1,045.08 725.40 44% 937.71 11% 3,313.90 2,349.38 41%

Guidance & outlook

  • ✓ Chemours project is targeted for completion by end of Q2 FY27
  • of Rs. 125 Crs is expected to operationalize by Q4 FY27

Growth & demand

  • levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its
  • Q1 FY27 – Sustainable growth

Margins & costs

  • Capex cost of phase II - Rs.125 Crs
  • Operating EBITDA 357.07 206.79 73% 321.15 11% 1,081.68 533.72 103%

Capex & expansion

  • ✓ De-bottlenecking MPP capacity at Dahej is on track for commissioning in Q3 FY27
  • ✓ Board had already approved cGMP4 capex of Rs. 288 Crs in Feb 24

Peers in Chemicals

Data for information only, not investment advice. Prices end of day.